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Abstract
Background: Optimising population-based cervical screening policies is becoming more complex due to the expanding
range of screening technologies available and the interplay with vaccine-induced changes in epidemiology. Mathematical
models are increasingly being applied to assess the impact of cervical cancer screening strategies.
Methods: We systematically reviewed MEDLINE®, Embase, Web of Science®, EconLit, Health Economic Evaluation
Database, and The Cochrane Library databases in order to identify the mathematical models of human papillomavirus
(HPV) infection and cervical cancer progression used to assess the effectiveness and/or cost-effectiveness of cervical
cancer screening strategies. Key model features and conclusions relevant to decision-making were extracted.
Results: We found 153 articles meeting our eligibility criteria published up to May 2013. Most studies (72/153) evaluated
the introduction of a new screening technology, with particular focus on the comparison of HPV DNA testing and
cytology (n = 58). Twenty-eight in forty of these analyses supported HPV DNA primary screening implementation. A
few studies analysed more recent technologies - rapid HPV DNA testing (n = 3), HPV DNA self-sampling (n = 4), and
genotyping (n = 1) - and were also supportive of their introduction. However, no study was found on emerging
molecular markers and their potential utility in future screening programmes. Most evaluations (113/153) were
based on models simulating aggregate groups of women at risk of cervical cancer over time without accounting
for HPV infection transmission. Calibration to country-specific outcome data is becoming more common, but has
not yet become standard practice.
Conclusions: Models of cervical screening are increasingly used, and allow extrapolation of trial data to project
the population-level health and economic impact of different screening policy. However, post-vaccination analyses
have rarely incorporated transmission dynamics. Model calibration to country-specific data is increasingly common
in recent studies.
Keywords: Systematic review, Human papillomavirus, Cervical cancer, Screening, Mathematical models, Economic
evaluations
Background
Cytological screening for cervical cancer is recognized as
having substantially reduced cervical cancer incidence and
mortality in many high-income countries (HIC). However,
recent technological developments are prompting a para-
digm shift in cervical cancer prevention [1]. Human papil-
lomavirus (HPV) DNA testing has greater sensitivity for
high-grade lesions than cytology when used as a primary
screening method, [2] while a panoply of other bio-
markers, such as p16, Ki-67, mRNA, and methylation
markers, have been investigated for their potential role in
primary screening, triage of borderline cytological out-
comes, and triage of HPV-positive results that could en-
able a fully molecular-based approach to screening [3].
Moreover, where introduced, HPV vaccination is expected
to eventually reduce the incidence of cervical cancer and
therefore reduce the absolute impact of existing screening
programmes, necessitating their reassessment for future
unvaccinated and vaccinated cohorts [4].
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Hence the choice of optimum cervical screening strat-
egies in future will be highly complex due to the number of
technological choices available, combined with epidemio-
logical changes in the target population. Mathematical
models offer a way to combine different types of evidence
about the choices available (together with their associated
uncertainty) to predict the impact of alternative prevention
strategies unlikely to be tested in clinical trials due to the
enormous time and resource requirements [5]. However,
the type of analysis used, the health technologies assessed,
and the modelling methods applied may have an important
impact on decision-making.
This is the first systematic review encompassing all
model-based effectiveness and/or cost-effectiveness ana-
lyses of cervical cancer screening strategies. Initial re-
views in this area [6,7] only examined cervical cancer
models analysing exclusively cytology-based strategies,
while those published after 2005 [5,8-10] focused only
on economic (and not epidemiological) models. There
have been three reviews of HPV DNA testing and cy-
tology for primary screening, [8-10] but only two [9,10]
were systematic. Other reviews have also examined HPV
DNA testing as triage for equivocal cytological outcomes
in high-income settings and visual inspection in low-
resource countries, [5] as well as a range of technologies in
the USA and in low-resource settings [11]. The limited
geographical scope of these reviews and the recent techno-
logical development justify a systematic review of the lit-
erature, including epidemiological evaluations, over the full
range of technologies available in any kind of setting.
The aims of this review are to (i) provide an overview
of results from all model-based economic evaluations of
cervical screening, in order to inform comprehensive
policy making on secondary prevention of cervical can-
cer, and (ii) identify trends and gaps in these models in
order to inform future work.
Methods
Search strategy
This review was conducted following guidance of the
Centre for Reviews and Dissemination for systematic re-
views [12] and Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [13]. We searched
the following electronic databases for studies published up
to May 2013: MEDLINE®; Embase; Web of Science®; EconLit;
the Health Economic Evaluations Database; and The
Cochrane Library including the NHS Economic Evaluation
Database and the Health Technology Assessment database
using the searches strategies in Additional file 1.
Selection criteria
We included original research articles that met the fol-
lowing criteria:
1. Based on mathematical modelling of HPV infection
and/or cervical disease progression
2. Estimated the impact of at least one cervical
screening technology/strategy
3. Estimated either clinical outcomes alone
(epidemiological models) or both clinical and
economic outcomes (economic models)
Studies modelling women of any age at risk of infec-
tion, infected, or who had been previously infected with
HPV were included, as well as studies on women with
concomitant infections (e.g. human immunodeficiency
virus (HIV)) or who had been treated for cervical lesions.
We included models of HPV vaccination where different
cervical screening strategies are compared to each other.
Economic evaluations (specifically cost-effectiveness ana-
lyses, cost-utility analysis, and cost-benefit analyses) were
included if they reported both costs and benefits expected
for each strategy of the analysis. Full texts for abstracts
and conference presentations identified as potentially rele-
vant in searches were sought, including initiating contact
with the corresponding authors when details were
otherwise unobtainable. Research articles published in
any language in peer-reviewed journals; and abstracts or
conference presentations from 2012 onwards published
with sufficient details to allow full completion of the
pre-established data extraction form were included.
Studies only comparing the costs of different strategies
were excluded, as well as publications that were neither
(i) archived by the British Library [14] nor (ii) published
in a journal included in the Thompson Reuters Impact
Factor list [15].
Study selection
Study selection was performed independently by two re-
viewers (DM and IB). Initially, the titles and abstracts of
the references retrieved in the searches were screened
according to the inclusion criteria defined above to iden-
tify potentially relevant studies. All titles and abstracts
were screened by at least one reviewer; 20% were inde-
pendently screened by both reviewers. Where initial as-
sessments differed, reviewers’ decisions and disagreements
were compared and discussed. Full papers of references
identified as potentially relevant in the initial screening
were then assessed for eligibility (ten per cent independ-
ently assessed by both reviewers). The reviewers again
compared results and discussed any differences. A third
reviewer (MJ) was consulted where consensus was not
reached in any of the screening stages.
Data extraction
Data extracted included name of first author, year of
publication, country of study, type of analysis, type of
model, calibration method, strategies/technologies assessed,
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and main findings. Additional file 2 provides a list of the
data extracted. The included studies were grouped by
World Health Organization (WHO) region [16] and level
of income of the analysed countries, as per the World
Bank 2014 income levels [17]. Studies referring to their re-
gion of interest as ‘developing countries’ were assumed to
relate to all WHO regions.
Results
The searches conducted identified 2,644 studies that po-
tentially met the inclusion criteria set out above. A
PRISMA [13] flow diagram of the selection of the in-
cluded studies is given below (Figure 1) and a completed
PRISMA checklist is provided as Additional file 3. From
screening titles and abstracts, 392 records were retrieved for
full screening, and 153 articles met the inclusion criteria.
Seventy-eight of the 153 publications included in this
review explicitly acknowledged that they were adapta-
tions or alternative applications (i.e. without changes to
the model assumptions) of previously published models.
The main characteristics of the studies included are
summarised in Figure 2 and are discussed further below.
Greater detail is provided in Additional files 4 and 5 that
present the characteristics of studies that focused on
screening alone and on combined screening and vaccin-
ation interventions, respectively, by year of publication.
Countries
Most included studies (n = 135) were based on a single
country. Additional file 6 shows the number of single- and
multiple-country studies by country. Forty-five countries
were addressed individually (either in single- or multiple-
country publications), ten of which – Argentina,
Barbados, Belgium, Chile, France, Finland, France, Iceland,
Ireland, Kenya, Mozambique, Tanzania, Uganda, and
Zimbabwe - were only analysed as part of multiple-
country studies. Figure 3 shows the distribution of the in-
cluded single-country studies on the world map. Over half
(80/153) of the studies focused on either the USA (n = 44),
the UK (n = 14), the Netherlands (n = 13), or Canada (n = 9).
The Americas, Europe, and/or Western Pacific regions
accounted for 86% of the studies.
Most studies focused exclusively on HIC (n = 117),
whereas 35 studies analysed low- and/or middle-income
countries, with 28 analysing only middle-income settings
and only 2 studies focusing entirely on low-income ones
[18,19]. One study analysed 6 regions of different
income-level [20].
Figure 1 PRISMA Flow diagram of study selection process. *Articles published in journals not included in the British Library catalogue or
Thompson Reuters Impact Factor (IF) list.
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Figure 2 Characteristics of included studies. *Exclusively these technologies; AFR, African Region; Auto; automated cytology; HPV, HPV DNA testing;
LMIC, low and middle income countries; VIA, VIA vs HPV DNA testing and cytology; WPR, Western Pacific Region.
Figure 3 Number of single-country studies per country.
Mendes et al. BMC Cancer  (2015) 15:334 Page 4 of 11
Type of analysis
Most studies (n = 129) included a cost-effectiveness ana-
lysis. Of these, 10 presented health outcomes in terms of
disease-specific measures only, 79 in terms of lives saved
or life years gained, and 40 in terms of the generic health
utility measure quality-adjusted life years (QALYs).
Quality-adjusted life years were particularly common
among studies assessing vaccination alongside screening
compared to those which assessed screening alone (42%
compared to 21%). There were no cost-benefit analyses
(i.e. studies in which both costs and outcomes were
expressed in monetary terms).
Figure 4 shows the distribution of studies by year ac-
cording to the type of analysis outcome (epidemiological
or economic) and the type of prevention strategies
assessed (screening alone or screening combined with
vaccination). Post-vaccination economic analyses have
become more common in the last decade and economic
analyses in general have become dominant compared
with studies analysing health outcomes only.
Type of intervention
The included studies estimated the incremental effect-
iveness or cost-effectiveness of three types of interven-
tions: (a) introduction of a new screening programme
where none existed before (n = 34), (b) changes to exist-
ing screening algorithms without the introduction of a
new technology (n = 47), and (c) introduction of a new
screening technology (n = 72).
a) Studies on the impact of introducing a new
screening programme (n = 34) were mostly
economic evaluations (n = 30). Most were set in
middle-income (n = 14) or high-income (n = 13)
countries. Several (n = 12) investigated screening
strategies post-HPV vaccine introduction. All 34
studies recommended introducing screening.
b) Studies exclusively analysing changes to existing
screening programmes examined alternative
cytology-based strategies (n = 47, 42 in HIC). Most
(18/23) studies making recommendations on screening
intervals or frequency endorsed an interval of 3 years
or more. Recommended starting ages ranged between
20–35 years old, while recommended stopping ages
ranged between 60–73 years old. Three studies looked
at rescreening cytology negative outcomes, and had
mixed results. One study examined follow-up of
women post-hysterectomy and recommended against
screening women over 40 years [21].
c) Seventy-two studies analysed the introduction of a
new screening technology to an existing programme.
All compared the new technology to cytology apart
from one study that compared visual inspection with
acetic acid (VIA) to HPV DNA testing. The findings
of these comparisons are detailed in the following
subsections.
Technologies assessed
Publications focused on cytology (n = 150), HPV DNA
(n = 77), and VIA (n = 12). Overall, the studies analysed
Figure 4 Number of studies by analysis and prevention type over time. Dark blue, Economic Screening; Light blue, Economic Screening & Vaccination;
Orange, Epidemiological Screening; Yellow, Epidemiological Screening & Vaccination.
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8 screening techniques: cytology (n = 150, of which 34
referred to liquid-based cytology (LBC)), cytology auto-
mated reading (e.g. Papnet© and AutoPap©, n = 7),
speculoscopy as adjunct to cytology (n = 1), HPV DNA
(n = 76), self-sampled HPV DNA testing (n = 4), HPV
16/18 genotyping (n = 1), and VIA (n = 12).
The main technological comparisons made were be-
tween (a) alternative cytology-based strategies (n = 77),
(b) HPV DNA versus cytology (n = 69), (c) VIA versus cy-
tology and/or HPV DNA (n = 11). Additional file 7 sum-
marises the findings on comparisons of technologies.
Alternative cytology-based strategies
Liquid-based cytology was recommended in 18/26 eco-
nomic analyses and in one epidemiological analysis com-
paring it with conventional cytology. The remaining
studies recommended conventional cytology (8/27) or
were equivocal (1/27).
Automated reading of cytological results was found to
be cost-effective when compared to manual reading in
all (n = 6) economic studies. One epidemiological study
on adding automated reading to LBC concluded that
evidence was still insufficient to recommend it relative
to manual reading [22]. One economic analysis found
the addition of speculoscopy to biennial conventional cy-
tology cost saving and health improving compared with
annual conventional cytology alone [23].
HPV DNA testing versus cytology alone
Several studies examined replacing cytology with HPV
DNA testing as the primary screening technique (n = 17)
and 15/17 studies found HPV DNA more cost-effective.
Twenty-four studies compared co-testing with cytology
and HPV DNA (n = 17), or with cytology primary
screening only (n = 7). Co-testing was supported in 6/7
studies comparing it with cytology; however, HPV DNA
testing was the most supported technology among stud-
ies comparing it with co-testing and cytology (10/17),
whilst 8/17 were favourable to co-testing, and 6/17 to
cytology alone for primary screening (some studies
supported more than one technology). Overall, HPV
DNA primary screening was supported in 26/34 studies
comparing it to cytology alone and/or co-testing.
The introduction of HPV DNA testing to triage minor
cytological abnormalities was supported in 9/10 studies
comparing it with repeat cytology and immediate referral
to colposcopy (7/8), immediate treatment (1/1), or co-
testing (1/1) in high- and middle-income countries.
Rapid and relatively-inexpensive HPV DNA testing
(careHPV™, n = 3) was found cost-effective in China
compared with VIA [24] or cytology, [25] as well as
when performed twice a lifetime alongside vaccination
compared with once a lifetime without vaccination,
provided affordable vaccination cost [26].
Most (3/4) economic analyses of post-treatment
screening [21,27-29] investigated the introduction of
HPV DNA testing. Two of these recommended its intro-
duction, [27,28] whereas one study found conventional
cytology the most cost-effective approach compared to
HPV DNA testing or LBC [29].
The introduction of self-sampled HPV DNA primary
screening instead of clinic-based HPV DNA testing or
conventional cytology was found cost-effective in 2/4
studies that looked at it.
One study on HPV 16/18 genotyping found it cost-
effective in the USA for triage of equivocal results of co-
testing (HPV DNA and LBC) compared with co-testing
alone, HPV DNA with LBC triage, LBC with HPV DNA
triage, or LBC alone [30].
VIA versus HPV DNA and/or cytology
All studies comparing VIA with HPV DNA and/or cytology
for primary screening (n = 11) were economic analyses and
most comparing HPV DNA testing and VIA (6/9) recom-
mended HPV DNA testing (n = 2) [19,31] or either (n = 4)
[18,20,32,33].
One study compared VIA with HPV DNA, cytology,
and self-sampling in South Africa and concluded that
1-visit HPV DNA testing was the most effective strategy,
slightly more costly than 1-visit VIA [32].
One study only comparing VIA and HPV DNA testing
found the latter cost-effective in low resource settings,
[19] and all studies comparing VIA with cytology only
(n = 2) supported VIA in MIC, [33,34] with one finding
cytology cost-effective to screen women over 50 years
old every 5 years in Thailand [35].
Screening and vaccination
Studies analysing screening strategies in vaccinated pop-
ulations (n = 35) assessed (a) the introduction of screen-
ing strategies where non-existent (n = 12), (b) changes to
existing cytology-based screening strategies (n = 12), and
(c) the introduction of new screening technologies in
existing programmes (n = 11).
a) Introducing screening (using any technology)
alongside vaccination was preferred over screening
alone by 10/12 studies (8 regarding low- and/or
middle-resource settings).
b) Most studies analysing changes to existing
cytology-based screening alongside vaccination
(10/12, 10 in high- and 2 in middle-income countries)
recommended combined screening and vaccination
interventions. Half of these studies highlighted the
importance of high coverage of screening and
immunization programmes. Recommendations on
cytology screening target age and interval varied
among HIC studies (n = 4).
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c) Studies on the introduction of screening
technologies post-vaccination looked largely at HPV
DNA testing and cytology (9/11, 2 in low and middle
income countries (LMIC)). HPV DNA testing alone
was found more cost-effective than cytology in 5/5
studies focused on primary screening with these
technologies alone. Studies comparing these with
co-testing as well (n = 3) concluded favourably
regarding co-testing [36-38]. One study explored
only the introduction of HPV DNA in triage of
cytological results, and supported it in the Netherlands,
Taiwan, and USA, but not in Canada or the UK [39].
Table 1 summarises the findings and recommenda-
tions of the studies included in this review.
Modelling methods
The modelling approaches used in the included studies
were classified according to the following dimensions [40]:
(a) Randomness (stochastic versus deterministic)
In deterministic models, events such as HPV acquisition
and clearance occur at a pre-determined rate. Stochastic
models incorporate randomness (stochasticity) in the
occurrence of these events, so the outcomes of a model
are not exactly the same each time it is run.
(b) Level (individual versus aggregate)
Individual-based models simulate and record the
events that occur in each modelled individual’s lifetime,
so that each individual has unique characteristics. In
contrast, aggregate models group individuals with simi-
lar characteristics into compartments, eliminating their
variability within each compartment. Hence individual-
based models capture population heterogeneity more
easily.
(c) Interaction (static versus dynamic)
If the rate at which people get infected with HPV (i.e.
the force of infection) is likely to change, such as follow-
ing population-based vaccination, then herd immunity
(i.e. indirect protection of susceptible individuals by a
significant proportion of immune individuals in the
population) is likely to affect the model results greatly.
Dynamic models account for herd immunity as the risk
of infection is modelled as dependent on the number of
infectious individuals rather than assumed to be con-
stant over time (static models).
The models found were mainly static (149/153), deter-
ministic (113/153) and aggregate (113/153); all aggregate
models were deterministic. Only 4 studies were dynamic
and all of these were deterministic and modelled individ-
uals at an aggregate level. Three of the four dynamic
models found were used to assess screening strategies
alongside vaccination. Similarly to models of screening in-
terventions alone, the models used for post-vaccination
analyses were mainly static (32/35), and deterministic ag-
gregate (19/35). Stochastic individual-based models were
more common among post-vaccination analyses (16/35;
46%) than amid those analysing screening interventions
alone (24/118; 20%).
Many models require values of parameters that are dif-
ficult to measure directly, such as the rate of progression
Table 1 Summary of findings and recommendations
Type of intervention
- Screening should be introduced (34/34, 100%)
- Cytology-based screening should have screening intervals ≥3 years
(18/23, 78%), starting age ≥25 years old (9/10, 90%), and stopping
age ≥60 years old (5/5, 100%)
- No post-hysterectomy screening follow-up should be given to
women >40 years old (1/1, 100%)
Technologies assessed
- Liquid-based cytology is recommended over conventional cytology
(18/27, 67%)
- Automated reading should be introduced (6/7, 86%)
- HPV DNA testing for primary screening is more cost-effective than
cytology (15/17, 88%)
- Co-testing is more cost-effective than cytology in HIC (6/7, 86%)
- HPV DNA testing is supported over co-testing and cytology alone
(10/17, 59%)
- HPV DNA to triage minor cytological abnormalities is endorsed over
(i)repeat cytology and immediate colposcopy (7/8), (ii)immediate
treatment (1/1), or (iii)co-testing (1/1) (9/10, 90%)
- HPV DNA testing for post-treatment screening should be introduced
(2/3, 67%)
- Rapid HPV DNA testing should be introduced in China (3/3, 100%)
- Self-sampled HPV DNA testing as primary screening in HIC is
cost-effective versus clinic-based HPV DNA or conventional cytology
alone(2/2, 100%); however, in upper-middle income countries, it is not
cost-effective versus other technologies, such as clinic-based HPV DNA
(2/2, 100%)
- HPV 16/18 genotyping should be introduced for triage of equivocal
results of co-testing versus co-testing alone, HPV DNA with LBC triage,
LBC with HPV DNA triage, or LBC alone (1/1, 100%)
- HPV DNA is more cost-effective than VIA in LMIC (1/1; 100%)
- VIA is more cost-effective than cytology in LMIC (2/2; 100%)
Screening and Vaccination
- Screening should be introduced even in a post-vaccination setting
(10/12, 83%)
- Screening should be continued after vaccination is introduced
(10/12, 83%)
- Post-vaccination HPV DNA primary screening is cost-effective compared
to cytology alone in HIC (5/5, 100%)
Figures in parentheses show the proportion (x/y) and percentage (%) of
relevant studies supporting each recommendation.
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from CIN3 to invasive cancer. Such values can be esti-
mated by calibrating the model, that is, adjusting its in-
ternal parameters until model outputs (such as cancer
incidence) match observational data. The extent to
which the outputs can match data is often quantified
using a goodness-of-fit measure. Commonly used quan-
titative goodness-of-fit measures include the sum of
squared residuals, the chi-squared statistic and the likeli-
hood of the data [41].
Most studies (n = 83) did not report having calibrated
their models at all. Of those that reported calibration
(n = 70), 21 did not specify the goodness-of-fit measure
used and 30 only assessed model fit to data visually
without using any quantitative goodness-of-fit measure.
The remaining studies (n = 19) explicitly reported using
a formal goodness-of-fit measure. A greater proportion
of models used for the assessment of screening strategies
alongside vaccination were calibrated (23/35; 66%) com-
pared with those of models only assessing screening
strategies (47/117; 40%).
Discussion
Many studies addressing a wide range of questions met
our inclusion criteria compared to that in other cervical
cancer-related reviews [42,43]. This may reflect the sub-
stantial global burden of cervical cancer, the recent de-
velopment of new screening methods and technologies,
as well as the role mathematical modelling has played
regarding context-specific policy questions that only very
large long term trials would address [43,44].
Results from model-based evaluations of cervical
screening
Most studies included a cost-effectiveness analysis
(129/153) and investigated the introduction of new
screening technologies (72/153), with fewer focusing ex-
clusively in alternative strategies using already-adopted
technologies (47/153), and even fewer on the introduction
of screening programmes where non-existent (34/153).
Evaluations of the introduction of a screening technology
were generally favourable to its adoption, with LBC rec-
ommended over conventional cytology (18/27), HPV DNA
recommended over cytology for primary screening (15/17),
rapid HPV DNA (3/3) or self-sampling (2/4) recommended
for primary screening, and HPV DNA (9/10) or genotyping
(1/1) recommended for triage of equivocal results.
Overall, our findings are in line with those of previous
reviews of cost-effectiveness analyses [5,8-11] and post-
vaccination analyses in the context of developed coun-
tries with existing screening programs [40], which
mostly recommend the introduction of HPV DNA pri-
mary screening in high-resource settings and the revi-
sion of screening policies towards the introduction of
HPV DNA primary testing.
As Nahvijou and colleagues also found, [10] there is a
discrepancy between guidelines and model-based evalua-
tions regarding more recent technologies. Generally,
current HIC screening guidelines ( Summary of cervical
screening guidelines provided in Additional file 8) are
aligned with the overall findings of evaluations of
cytology-based strategies; however, most concluded lack-
ing sufficient evidence on the effectiveness of HPV DNA
testing for primary screening to support its implementa-
tion, [45] with only a few countries, such as Australia,
the Netherlands and the USA, recommending it at the
moment.
Trends and gaps identified
Most of the global cervical cancer burden lies in low-
and middle-income countries without organised screen-
ing programmes [46] However, as noted in previous re-
views, [5,11] only a small proportion of studies in our
review (34/153) addressed these settings, with the vast
majority (33/34) supporting the existence of a screening
programme. Indeed, over half the studies (80/153) were
set in just 4 HIC – the USA, the UK, the Netherlands,
or Canada. More evaluations focused on the regions
with the greatest cervical cancer burden may have
greater influence in driving adoption of screening tech-
nologies where they are most needed.
Currently several molecular biomarkers are being in-
vestigated for their potential to be integrated alongside
cytology and HPV DNA testing in screening algorithms.
However, no model-based study was found in this review
on these emerging screening technologies. Only a few
studies analysed more recent technologies as rapid HPV
DNA testing, self-sampled HPV DNA testing, or HPV
16/18 DNA genotyping. No study on rapid HPV DNA
testing was found in a low-income setting either.
Some molecular-based tests are thought to have the
potential to improve cytology’s accuracy and reproduci-
bility (e.g. p16 immunostaining), while other are thought
to be promising alternatives to cytology (e.g. HPV DNA
testing, HPV mRNA testing, p16/ki-67 dual immuno-
staining, or methylation markers) as they can be subject
to automated quantification [47]. The clinical utility of
HPV DNA testing has been shown, [2] and it has re-
cently been introduced in primary screening in a few
HIC, e.g. the Netherlands and Ontario [48]. These re-
cent developments in screening technologies may sug-
gest a transition to a fully molecular-based screening
approach. However, the population-level effectiveness
and cost-effectiveness behind many of the molecular
technologies is still unexplored. For most biomarkers
there is currently only cross-sectional evidence of their
potential accuracy [3]. HPV mRNA testing for instance
has been recently approved by the U.S. Food and Drug
Administration for screening women over 30 years in
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combination with cytology, despite evidence from longi-
tudinal trials of its improved accuracy in the detection of
CIN2+ lesions who do not regress be not yet available
[49]. Mathematical models are a key tool to allow results
from trials and observational studies of these technolo-
gies to be extrapolated to explore their long-term impact
in population-based screening programmes.
Another aspect of research that can be explored via
mathematical modelling is the interaction between vac-
cination and screening. Vaccinating adolescent girls has
been found likely to be cost-effective even in settings
with existing screening programmes [40,50]. However,
vaccination is expected to decrease the incidence of cer-
vical abnormalities and eventually cancer [51]. Hence
the positive predictive value of cytology will decrease, as
will the effectiveness of most screening modalities. [43,52]
In order to assist in population level policy making, future
analyses in settings with vaccination will need to account
for its impact on existing and prospect screening pro-
grammes. This is particularly true if a 9-valent HPV
vaccine is successful in trials, as it is projected to ultimately
prevent 90% of invasive cervical cancers [53].
Also, most models of screening in post-vaccination
settings relied on a static infection structure. This may
be suitable for comparing alternate screening strategies
in a setting in which disease prevalence is constant, but
would not capture the long-term changes in HPV preva-
lence, in settings with successful national HPV vaccin-
ation programmes [54] such as the UK, Australia and
Portugal. Dynamic transmission models are particularly
important now that a 9-valent HPV vaccine has shown
high immunogenicity and efficacy in clinical trials [55].
This will have further implications on cervical screening
since vaccinated girls will have a very low risk of infec-
tion with an oncogenic HPV type and hence risk of
cervical cancer. The few dynamic models compared
alternative cytology-based strategies [56,57] or strategies
with rapid HPV DNA testing versus vaccination only or
alongside vaccination [26]. Their overall results were
consistent with those of static models in that screening
strategies alongside vaccination maximise health out-
comes. However, it can take many years for the direct
and indirect impact of vaccination to be observed in sur-
veillance data, so dynamic models will be increasingly
important to explore changes to screening as the first
vaccinated cohorts enter the age of screening eligibility.
Model calibration to observed setting-specific data has
become more common; however it is still not routinely
used. As most natural history parameters governing the
progress of cervical abnormalities are very difficult to
measure directly, model calibration enables their estima-
tion based on observable outcomes such as abnormal
screening results. This is generally a more reliable ap-
proach than making assumptions on parameters based
on limited studies, often in unrepresentative populations
[41,58]. Even the studies reporting having calibrated
these parameters to outcome data often gave few details
about the goodness-of-fit measure used and very rarely
provided details on other aspects of calibration, such as
the selection of calibration targets, parameter search
strategies, and convergence criteria used. Detailed
reporting of the calibration process should be common
practice for reproducibility purposes [59]. Also, there
should be an indication of uncertainty in the parameter
estimates used and how it is incorporated to judge the
sensitivity of model predictions to the data sources used.
This review is subjected to limitations. We focused on
models used to assess the impact of alternative screening
strategies, and excluded model-based studies assessing
vaccination strategies, including those modelling screen-
ing strategies alongside vaccination that did not compare
different screening strategies. Because of the volume and
diversity of the relevant modelling literature, we did not
critically appraise the quality of individual studies, but
instead focused on providing an overview of the main
approaches and conclusions of the models. Further work
is needed to critically review modelling literature that
addresses specific questions (such as the choice between
cytological and DNA-based screening methods) in more
detail. The main strength of our work lies in providing a
broad overview of the vast literature over a long time
period, and in identifying key conclusions that are com-
mon across models as well as gaps in the methodology
and scope of current models.
Conclusions
The main questions addressed over time by models used
to assess cervical cancer screening strategies focused on
high-income settings analysing matters relevant to LMIC
as well, such as the introduction of HPV DNA testing
and more recently the most appropriate post-vaccination
screening strategy. Despite the increasingly large number
of publications, few studies investigated the utility of
HPV DNA self-sampling and genotyping in future
screening programmes, and none explored the potential
role of emergent molecular markers. Transmission dy-
namics have rarely been incorporated and model calibra-
tion is not standard practice yet. Dynamic models fitted
to country-specific data could be helpful tools to investi-
gate future post-vaccination screening strategies.
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